Drug target · SLC6A2
NET
Sodium-dependent noradrenaline transporter
9 compounds in the CNS pipeline act on NET.
Compounds targeting NET
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| CentanafadineprimarySmall molecule | Reuptake inhibitor | IC50 6 nM | ApprovedAttention-deficit/hyperactivity disorder | Otsuka Pharmaceutical Co., Ltd. |
| Solriamfetol (Sunosi)primarySmall molecule | Reuptake inhibitor | Ki 3700 nM | ApprovedExcessive daytime sleepiness | Axsome Therapeutics, Inc. |
| AXS-12 (reboxetine)primarySmall molecule | Reuptake inhibitor | pKi 8 | Filed (NDA)Narcolepsy | Axsome Therapeutics, Inc. |
| AXS-14 (esreboxetine)primarySmall molecule | Reuptake inhibitor | — | Phase 3Fibromyalgia | Axsome Therapeutics, Inc. |
| PDC-1421primaryNatural product | Reuptake inhibitor | — | Phase 2Major depressive disorder | ABVC BioPharma, Inc. |
| AmpreloxetineprimarySmall molecule | Reuptake inhibitor | pKi 8.8 | DiscontinuedMultiple System Atrophy | Theravance Biopharma, Inc. |
| Methylone (TSND-201)Psychedelic | Releaser | — | Phase 3Post-traumatic stress disorder | Transcend Therapeutics, Inc. |
| EMP-01 (oral R-MDMA)Psychedelic | Releaser | — | Phase 2Social anxiety disorder | EmpathBio, Inc. |
| OPC-64005Small molecule | Reuptake inhibitor | — | DiscontinuedMajor depressive disorder | Otsuka Pharmaceutical Co., Ltd. |